Over the past several years, there has been increasing recognition of TRALI as a serious complication of transfusion. Various approaches to mitigating TRALI risk for high plasma volume blood products have been discussed and, in some cases, implemented. In the case of transfusable plasma products, a common approach has been the use of male predominant plasma. In the case of apheresis platelets, there has been little consensus on what approach should be used with much controversy over the need for leukocyte antibody testing of some or all apheresis donors. The pros and cons of various approaches will be discussed and data on current practices from a soon to be completed survey of AABB members will be presented.